AIDSVAX


Also found in: Wikipedia.

AIDSVAX

A vaccine produced by VaxGen which failed to protect those receiving the vaccine from developing AIDS, although some data suggested that it may benefit African Americans. VaxGen has continued to expand the trials. The results of the Phase II trials were underwhelming, so VaxGen piggybacked it with the Aventis-Pasteur vaccine, ALVAC-HIV. Data from the combination vaccine, ALVAC-AIDSVAX B/E, has shown an efficacy ranging from 26 to 31% (N Engl J Med 2009; 361: 23, 2209-2220).
References in periodicals archive ?
Nitayaphan et al., "Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand," The New England Journal of Medicine, vol.
Concurrently, the eligible participants in HVTN 114 will receive either another MVA62B boost, a combined boost of MVA62B and AIDSVAX B/E, or AIDSVAX B/E alone.
(8.) Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al., Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
This in turn led to a new trial (RV 144 in Thailand) to test a canarypox vector vaccine (ALVAC-HIV) boosted with a recombinant glycoprotein vaccine (AIDSVAX B/E).
AIDSVAX. La compania Vaxgen presento esta vacuna que consistia en tomar 2 fragmentos de gp 120 para recombinarlos y provocar la produccion de anticuerpos en pacientes con VlH para desactivar el virus y que este no pudiera unirse a o invadir las celulas susceptibles (linfocitos T), pero fallo en proveer cualquier proteccion.
Results from a recent vaccine trial in Thailand demonstrated preliminary efficacy of a combination ALVAC-HIV and AIDSVAX B/E vaccine regimen among a community-based sample consisting mostly of relatively low-risk heterosexuals (Rerks-Ngarm et al.
It was designed to prime HIV-1-specific cell-mediated immunity and was then followed by two injections of a recombinant glycoprotein gp120 subunit vaccine containing concentrations of subtype B and E antigens designed to boost HIV-1 cell-mediated immunity and stimulate neutralising HIV-1 antibodies (AIDSVAX) [5].
The booster dose, AIDSVAX B/E, is a glycoprotein 120 vaccine.
The unexpected result puzzled researchers, who say they cannot figure out why the drug - a combination of canary pox vaccine and the failed HIV vaccine Aidsvax - is working.
The vaccines used during the trials were ALVAC, from Sanofi Pasteur, the vaccine division of French drugmaker Sanofi-Aventis and AIDSVAX, developed by VaxGen Inc.
They are ALVAC, from Sanofi Pasteur, the vaccine division of French drugmaker Sanofi-Aventis; and AIDSVAX, originally developed by VaxGen Inc.
The vaccine is a combination of Sanofi-Aventis ALVAC canary pox vaccine and HIV vaccine AIDSVAX, made by VaxGen, Reuters reported.